Effects of 4-aminopyridine on motor evoked potentials in patients with spinal cord injury

Journal of Neurotrauma

Volumn 14, Issue 3, 1997, Pages 135-148

  Qiao, J ^a   Hayes, K C ^a,b   Hsieh, J T C ^a   Potter, P J ^a   Delaney, G A ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b PARKWOOD HOSPITAL   (Canada)

Author keywords

4 aminopyridine; central motor conduction deficits; motor evoked potentials; patients; spinal cord injury

Indexed keywords

4 AMINOPYRIDINE; POTASSIUM CHANNEL BLOCKING AGENT;

ADULT; ARTICLE; BRAIN DEPTH STIMULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EVOKED MUSCLE RESPONSE; EXTENSOR MUSCLE; FEMALE; HUMAN; MALE; MOTOR NERVE CONDUCTION; MUSCLE REFLEX; ORAL DRUG ADMINISTRATION; SPINAL CORD INJURY;

EID: 0030958125     PISSN: 08977151     EISSN: None     Source Type: Journal    
DOI: 10.1089/neu.1997.14.135     Document Type: Article

References (81)

1. AGOSTON, S., SALT, P.J., ERDMANN, W., HIULKMEUER, T., BENCINI, A., and LANGREHR, D. (1980). Antagonism of ketamine-diazepam anaesthesia by 4-aminopyridine in human volunteers. Br. J. Anaesth. 52, 367-370.
2. AGOSTON, S., VAN WEERDEN, T., WESTRA, P., and BROEKERT, A. (1978). Effects of 4-aminopyridine in Eaton Lambert Syndrome. Br. J. Anaesth. 50, 383-385.
3. BALL, A.P., HOPKINSON, R.B., FARRELL, I.D., et al. (1979). Human botulism caused by clostridium botulinum type e - The Birmingham Outbreak. Quart. J. Med. 48, 473-491.
4. BARKER, A.T., FREESTON, I.L., JALINOUS, R., and JARRATT, J.A. (1988). Magnetic and electrical stimulation of the brain: Safety aspects, in Neurology and Neurobiology, Vol 41, Non-invasive Stimulation of Brain and Spinal Cord: Fundamentals and Clinical Applications, P.M. Rossini and C.D. Marsden (eds.). Alan R. Liss, Inc.: New York, pp. 131-144.
5. BEVER, C.T., JR. (1994). The current status of studies of aminopyridines in patients with multiple sclerosis. Annals of Neurology 36, S118-121.
6. BEVER, C.T., JR., YOUNG, D., ANDERSON, P.A., KNUMHOLZ, A., et al. (1994). The effects of 4-aminopyridine in multiple sclerosis patients: Results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology 44, 1054-1059.
7. BLIGHT, A.R. (1989). Effect of 4-aminopyridine on axonal conduction-block in chronic spinal cord injury. Brain Res. Bull. 22, 47-52.
8. BLIGHT, A.R., and GRUNER, J.A. (1987). Augmentation by 4-aminopyridine of vestibulospinal free fall responses in chronic spinal-injured cats. J. Neurol. Sci. 87, 145-159.
9. BLIGHT, A.R., TOOMBS, J.P., BAUER, M.S., and WIDMER, W.R. (1991). The effects of 4-aminopyridine on neurological deficits in chronic cases of traumatic spinal cord injury in dogs: A Phase I clinical trial. J. Neurotrauma 8, 103-119.
10. BOSTOCK, H., SHERRATT, R.M., and SEARS, T.A. (1978). Overcoming conduction failure in demyelinated nerve fibres by prolonging action potentials. Nature 274, 385-387.
11. BOSTOCK, H., SEARS, T.A., and SHERRATT, R.M. (1981). The effects of 4-aminopyridine and Tetraethylammonium ions on normal and demyelinated mammalian nerve fibres. J. Physiol. 313, 301-315.
12. BOWE, C.M., KOCSIS, J.D., TARG, E.F., and WAXMAN, S.G. (1987). Physiological effects of 4-aminopyridine on demyelinated mammalian motor and sensory fibers. Ann. Neurol. 22, 264-268.
13. BOWMAN, W.C., and SAVAGE, A.O. (1981). Pharmacological actions of aminopyridines and related compounds. Rev. Pure Applied Pharmacol. Sci. 2, 317-371.
14. BRISMAR, T.A. (1979). Potential clamp experimentation on myelinated nerve fibres from alloxan diabetic rats. Acta Physiol Scand 105, 384-386.
15. BUNGE, R.P., PUCKETT, W.R., BECERRA, J.L., MARCILLO, A., and QUENCER, R.M. (1993). Observations on the pathology of human spinal cord injury. A review and classification of 22 new cases with details from a case of chronic cord compression with extensive focal demyelination, in Neural Regeneration. F.J. Seil (ed.). Raven Press: New York, Vol. 59, pp. 75-89.
16. DAVIS, F.A., STEFOSKI, D., and RUSH, J. (1990). Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis. Ann. Neurol. 27, 186-192.
17. DAVIS, F.A., STEFOSKI, D., and QUANDT, F.N. (1995). Mechanism of action of 4-aminopyridine in the symptomatic treatment of multiple sclerosis. Ann. Neurol. 37, 684.
18. DUBUC, R., and ROSSIGNOL, S. (1989). The effects of 4-aminopyridine on the cat spinal cord: rhythmic antidromic discharges recorded from the dorsal roots. Brain Res. 491, 335-348.
19. DUBUC, R., ROSSIGNOL, S., and LAMARRE, Y. (1986). The effects of 4-aminopyridine on the spinal cord: Rhythmic discharges recorded from the peripheral nerves. Brain Research 369, 243-259.
20. EIDELBERG, J.L., STORY, J.L., WALDEN, J.G., and MEYER, B.L. (1981a). Anatomical correlates of return of locomotor function after partial spinal cord lesions in cats. Experimental Brain Research 42, 81-88.
21. EIDELBERG, J.L., WALDEN, J.G., and NGUYEN, L.H. (1981b). Locomotor control in macaque monkeys. Brain 104, 647-663.
22. FEHLINGS, M.G., and TATOR, C.H. (1995). The relationships among the severity of spinal cord injury, residual neurological function, axon counts, and counts of retrogradely labelled neurons after experimental spinal cord injury. Exp. Neurol. 132, 220-228.
23. FEHLINGS, M.G., and NASHMI, R. (1996). Changes in pharmacological sensitivity of the spinal cord to potassium channel blockers following acute spinal cord injury. Brain Res. (in press).
24. GLOVER, W.E. (1982). The aminopyridines. Gen. Pharmac. 13, 259-285.
25. HAGHIGHI, S.S., PUGH, S.L., PEREZ-ESPEJO, M.A., and ORO, J.J. (1995). Effect of 4-aminopyridine in acute spinal cord injury. Surgical Neurology 43, 443-447.
26. HANSEBOUT, R.R., BLIGHT, A.R., FAWCETT, S., and REDDY, K. (1993). 4-aminopyridine in chronic spinal cord injury: a controlled, double-blind, crossover study in eight patients. J. Neurotrauma 10, 1-8.
27. HAYES, K.C. (1994). 4-aminopyridine and spinal cord injury: a review. Restor. Neurol. Neurosci. 6, 259-270.
28. HAYES, K.C., ALLATT, R.D., WOLFE, D.L., KASAI, T., and HSIEH, J.T.C. (1991b). Reinforcement of motor evoked potentials in patients with spinal cord injury, in Magnetic Motor Stimulation: Basic Principles and Clinical Experience (EEG Suppl 43). W.J. Levy, R.Q. Cracco, A.T. Barker, and J. Rothwell (eds.). Amsterdam: Elsevier Science Publishers, BV., pp. 312-329.
29. HAYES, K.C., POTTER, P.J., WOLFE, D.L., HSIEH, J.T., DELANEY, G.A., and BLIGHT, A.R. (1994). 4-aminopyridine sensitive neurological deficits in patients with spinal cord injury. J. Neurotrauma 11, 433-446.
30. HAYES, K.C., BLIGHT, A.R., ALLATT, R.D., HAMILTON, J.T., POTTER, P.J., BROWN, W.F., WOLFE, D.L., HSIEH, J.T.C, and LAM, S. (1991a). Effects of intravenous 4-aminopyridine on neurological function in chronic spinal cord injured patients: Preliminary observations. Proc. IBRO World Conf. Neurosci. 345, P53.27.
31. HAYES, K.C., BLIGHT, A.R., POTTER, P.J., ALLATT, R.D., HSIEH, J.T.C., WOLFE, D.L., LAM, S., and HAMILTON, J.D. (1993). Preclinical trial of 4-aminopyridine in patients with chronic spinal cord injury. Paraplegia 31, 216-224.
32. JANKOWSKA, E., LUNDBERG, A., RUDOMIN, P., and SYKOVA, E. (1977). Effects of 4-aminopyridine on transmission in excitatory and inhibitory synapses in the spinal cord. Brain Res 136, 387-388.
33. JANKOWSKA, E., LUNDBERG, A., RUDOMIN, P., and SYKOVA, E. (1982). Effects of 4-aminopyridine on synaptic transmission in the cat spinal cord. Brain Res 240, 117-129.
34. JASPER, H.H. (1958). The ten-twenty electrode system of the International Federation. Electroencephalogr. Clin. Neurophysiol. 10, 371-375.
35. JONES, R.E., HERON, J.R., FOSTER, D.H., SNELGAR, R.S., and MASON, R.J. (1983). Effects of 4-aminopyridine in patients with multiple sclerosis. J. Neurol. Sci. 60, 353-362.
36. KAELAN, C., JACOBSEN, P., MORLING, P., and KAKULAS, B.A. (1989). A quantitative study of motoneurons and cortico-spinal fibres related to function in human spinal cord injury (SCI). Paraplegia 27, 148-153.
37. KIM, Y.I., GOLDNER, M.M., and SANDERS, D.B. (1980). Facilitatory effects of 4-aminopyridine on normal neuromuscular transmission. Muscle & Nerve 3, 105-111.
38. KIMURA, J. (1989). Electrodiagnosis in Diseases of Nerve and Muscle: Principles and Practice Edition 2, F.A. Davis Company: Philadelphia.
39. KIRCHHOFF, C., LEAH, J.D., JUNG, S., and REEH, P.W. (1992). Excitation of cutaneous sensory nerve endings in the rat by 4-Aminopyridine and tetraethylammonium. J. Neurophysiol. 67, 125-131.
40. KIRSCH, G.E., and DREWE, J.A. (1993). Gating-dependent mechanism of 4-aminopyridine block in two related potassium channels. J. Gen. Physiol. 102, 797-816.
41. KLEINBAUM, D.G., and KUPPER, L.L. (1978). Applied Regression Analysis and Other Multivariable Methods. North Scituate, MA: Duxbury Press.
42. KOCSIS, J.D. (1985). Aminopyridine sensitivity of spinal cord white matter studied in vitro. Exp. Brain Res. 57, 620-624.
43. KOCSIS, J.D., BOWE, C.M., and WAXMAN, S.G. (1986). Different effects of 4-aminopyridine on sensory and motor fibers: Pathogenesis of paresthesias. Neurology 36, 117-120.
44. KOCSIS, J.D., RUIZ, J.A., and WAXMAN, S.G. (1983). Maturation of mammalian myelinated fibres: changes in action potential characteristics following 4-aminopyridine application. J. Neurophysiol 50, 449-463.
45. LEMEIGNAN, M. (1972). Analysis of the action of 4-aminopyridine on the cat lumbar spinal cord I. Modification of the afferent volley, the monosynaptic discharge, amplitude and the polysynaptic evoked responses. Neuropharmacology 11, 551-558.
46. LEMEIGNAN, M. (1973). Analysis of the effect of 4-aminopyridine on the lumbar spinal cord of the cat-II. Modification of certain spinal inhibitory phenomena post-tetanic potentiation and dorsal root potential. Neuropharmacology 12, 641-651.
47. LEMEIGNAN, M., MILLART, H., LAMIABLE, D., MOLGO, J., and LECHAT, P. (1986). Evaluation of 4-aminopyridine and 3,4-diaminopyridine penetrability into cerebrospinal fluid in anaesthetized rats. Brain Res. 304, 166-169.
48. LUNDH, H., NILSSON, O., and ROSEN, I. (1977). 4-aminopyridine - A new drug tested in the treatment of Eaton-Lambert syndrome. J. Neurol. Neurosurg. Psychiatry 40, 1109-1112.
49. LUNDH, H., NILSSON, O., and ROSEN, I. (1979). Effects of 4-aminopyridine in myasthenia gravis. J. Neurol. Neurosurg. Psychiatry 42, 171-175.
50. LUNDH, H., and THESLEFF, S. (1977). The mode of action of 4-aminopyridine and guanidine on transmitter release from motor nerve terminals. Eur. J. Pharmacol. 42, 411-412.
51. MILLER, R.D., BOOIJ, L.H.D.J., AGOSTON, S., and CRUL, J.F. (1979). 4-aminopyridine potentiates neostigmine and pyridostigmine in man. Anaesthesiology, 50, 416-420.
52. MOLGO, J., LEMEIGNAN, M., and LECHAT, P. (1997). Effects of 4-aminopyridine at the frog neuromuscular junction. J. Pharmac. Exp. Ther. 203, 653-663.
53. MOLGO, J., LUNDH, H., and THESLEFF, S. (1980). Potency of 3,4-diaminopyridine and 4-aminopyridine on mammalian neuromuscular transmissions and the effect of pH changes. Eur. J. Pharmac. 61, 25.
54. MURRAY, N.M.F., and NEWSOM-DAVIS, J. (1981). Treatment with oral 4-aminopyridine in disorders of neuromuscular transmission. Neurology 31, 265-271.
55. PASKOV, D.S., AGOSTON, S., and BOWMAN, W.C. (1986). 4-aminopyridine hydrochloride (Pymadin), in New Neuromuscular Blocking Agents-Basic and Applied Aspects, Handbook of Experimental Pharmacology. D.A. Charkavich (ed.). New York: Springer-Verlag: vol. 79, pp. 679-717.
56. POLMAN, C.H., BERTELSMANN, F.W., VAN LOENEN, A.C., and KOETSIER, J.C. (1994a). 4-aminopyridine in the treatment of patients with multiple sclerosis: long-term efficacy and safety. Arch. Neurol. 51, 292-296.
57. POLMAN, C.H., BERTELSMANN, F.W., DE WAAL, R., VAN DIEMEN, H.G.A.M., IITDCHAAG, B.M.J., VAN LOENEN, A.C., and KOETSIER, J.C. (1994b). 4-aminopyridine is superior to 3,4-Diaminopyridine in the treatment of patients with multiple sclerosis. Arch. Neurol. 51, 1136-1139.
58. POTTER, P.J., HAYES, K.C., HSIEH, J.T.C., DELANEY, G.A., and SEGAL, J.L. (1997). Sustained improvements in neurological function in spinal cord injured patients treated with oral 4-aminopyridine: 3 cases. Spinal Cord (in press).
59. PRATT, K., TOOMBS, J.P., WIDMER, W.R., and BORGENS, R.B. (1995). Plasma and cerebrospinal fluid concentrations of 4-aminopyridine following intravenous injection and metered intrathecal delivery in canines. J. Neurotrauma 12, 23-39.
60. RITCHIE, J.M. (1982). Sodium and potassium channels in regenerating and developing mammalian myelinated nerves. Proc. R. Soc. Lond. 215, 273-287.
61. ROBINSON, L.R., JANTRA, P., and MACLEAN, I.C. (1988). Central motor conduction times using transcranial stimulation and F-wave latencies. Muscle & Nerve 11, 174-180.
62. SAADE, N., JABBUR, S.J., and WALL, P.D. (1985). Effects of 4-aminopyridine, GABA and bicuculline on cutaneous receptive fields of cat dorsal horn neurons. Brain Res. 344, 356-359.
63. SAADE, N.E., BANNA, N.R., KHOURY, A., JABBUR, S.J., and WALL, P.D. (1982). Cutaneous receptive field alterations induced by 4-aminopyridine. Brain Res. 232, 177-180.
64. SAADE, N.E., CHANELET, J., and LONCHAMPT, P. (1971). Action facilitratrice de microinjection de 4-aminopyridine sur les activités medullaries reflexes de la grenouille. CR Soc. Biol. 165, 2069-2078.
65. SANDERS, D.B., KIM, Y.I., HOWARD, J.F., and GOETSCH, C.A. (1980). Eaton Lambert syndrome: A clinical and electrophysiological study of a patient treated with 4-aminopyridine. J. Neurol. Neurosurg. 43, 978-985.
66. SEGAL, J.L., HAYES, K.C., BRUNNEMAN, S., and HSIEH, J.T.C. (1997). Pharmacokinetics of oral 4-AP in SCI patients. (submitted).
67. SHERRATT, R.M., BOSTOCK, H., and SEAR, T.A. (1980). Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibers. Nature 283, 570-572.
68. SMITS, R.C., EMMEN, H.H., BERTELSMANN, F.W., KULIG, B.M., VANLOENEN, A.C., and POLMAN, C.H. (1994). The effects of 4-aminopyridine in cognitive function in patients with multiple sclerosis: A pilot study. Neurology 44, 1701-1705.
69. SONI, N., and KAM, P. (1982). 4-aminopyridine-A Review. Anaesth. Intens. Care 10, 120-126.
70. STEFOSKI, D., DAVIS, F.A., FITZSIMMONS, W.E., LUSKIN, S.S., RUSH, J., and PARKHURST, G.W. (1987). 4-aminopyridine in multiple sclerosis: Prolonged administration. Neurology 41, 1344-1348.
71. STEFOSKI, D., DAVID, F.A., FITZSIMMONS, W.E., LUSKIN, S.S., RUSH, J., and PARKHURST, G.W. (1991). 4-aminopyridine improves clinical signs in multiple sclerosis. Ann. Neurol. 21, 71-77.
72. TARG, E.F., and KOCSIS, J.D. (1985). 4-aminopyridine leads to restoration of conduction in demyelinated rat sciatic nerve. Brain Res. 328, 358-361.
73. TASAKI, I. (1953). Nervous Transmission. Charles C. Thomas: Springfield, IL.
74. THESLEFF, S. (1980). Aminopyridine and synaptic transmission. Neurosciences 5, 1413-1419.
75. UGES, D.R.A., SOHN, Y.J., GREIJDANUS, B., SCAF, A.H.J., and AGOSTON, S. (1982). 4-aminopyridine kinetics. Clin. Pharmacol. Ther. 31, 587-593.
76. VAN DIEMEN, H.A., POLMAN, C.H., VAN DONGEN, T.M., VAN LOENEN, A.C., NAUTA, J.J., TAPHOORN, M.J., VAN WALBEEK, H.K., and KOETSIER, J.C. (1992). The effect of 4-aminopyridine on the clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, crossover study. Ann. Neurol. 32, 123-130.
77. WAXMAN, S.G. (1989). Demyelination in spinal cord injury. J. Neurol. Sci. 91, 1-14.
78. WAXMAN, S.G. (1993). Aminopyridines and the treatment of spinal cord injury. J. Neurotrauma 10, 19-24.
79. WAXMAN, S.G., KOCSIS, J.D., and ENG, D.L. (1985). Ligature-induced injury in peripheral nerve: Electrophysiological observations on changes in action potential characteristics following blockade of potassium conductance. Muscle & Nerve 8, 85-92.
80. WINDLE, W.F., SMART, J.O., and BEERS, J.J. (1958). Residual function after subtotal spinal cord transection in adult cats. Neurology 8, 518-521.
81. ZANGGER, P. (1981). The effect of 4-aminopyridine on the spinal locomotor rhythm induced by L-Dopa. Brain Res. 215, 211-223.